Rolf Jenni

Rolf Jenni

Auto-generated profile, based on publicly available information

Rolf Jenni


Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2001 in Heart
Verified
Journal Article
Open access
PDF file
RJR Jenni
R Jenni
EOE Oechslin
E Oechslin
JSJ Schneider
J Schneider
CJC Attenhofer Jost
C Attenhofer Jost
PKP A Kaufmann
P A Kaufmann
AIM To determine clear cut echocardiographic criteria for isolated ventricular non-compaction (IVNC), a cardiomyopathy as yet “unclassified” by the World Health Organization. The disease is not widely known and its diagnosis mostly missed. METHODS AND RESULTS In seven out of a series of 34 patients with IVNC the in vivo echocardiographic characteristics were validated against the anatomical examination of the heart removed after death in four and due to heart transplantation in three patients. Four morphological criteria diagnostic for IVNC were found. (1) Coexisting cardiac abnormalities were absent (by definition). (2) A two layer structure was seen, with a compacted thin epicardial band and a much thicker non-compacted endocardial layer of trabecular meshwork with deep endomyocardial spaces. A maximal end systolic ratio of non-compacted to compacted layers of > 2 is diagnostic. (3) The predominant localisation of the pathology was to mid-lateral (seven of seven patients), apical (six), and mid-inferior (seven) areas. The pathological preparations confirmed the echocardiographic findings. Concomitant regional hypokinesia was not confined to the non-compacted segments. (4) There was colour Doppler evidence of deep perfused intertrabecular recesses. CONCLUSIONS Four clear cut echocardiographic diagnostic criteria were established. It is suggested that the WHO classification of cardiomyopathies be reconsidered to include IVNC as a distinct cardiomyopathy.

1 August 2000 in JACC
Verified
Journal Article
Closed access
EOErwin N Oechslin
Erwin N Oechslin
CJChristine H Attenhofer Jost
Christine H Attenhofer Jost
JRJerry R Rojas
Jerry R Rojas
PKPhilipp A Kaufmann
Philipp A Kaufmann
RJRolf Jenni
Rolf Jenni

1 January 1997 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
MRManfred Ritter
Manfred Ritter
EOErwin Oechslin
Erwin Oechslin
GSGabor Sütsch
Gabor Sütsch
CAChristine Attenhofer
Christine Attenhofer
JSJakob Schneider
Jakob Schneider
RJRolf Jenni
Rolf Jenni

3 June 2008 in Circulation
Verified
Journal Article
Closed access
SKSabine Klaassen
Sabine Klaassen
SPSusanne Probst
Susanne Probst
EOErwin Oechslin
Erwin Oechslin
BGBrenda Gerull
Brenda Gerull
GKGregor Krings
Gregor Krings
LTLudwig Thierfelder
Ludwig Thierfelder
Background— Left ventricular noncompaction constitutes a primary cardiomyopathy characterized by a severely thickened, 2-layered myocardium, numerous prominent trabeculations, and deep intertrabecular recesses. The genetic basis of this cardiomyopathy is still largely unresolved. We speculated that mutations in sarcomere protein genes known to cause hypertrophic cardiomyopathy and dilated cardiomyopathy may be associated with left ventricular noncompaction. Methods and Results— Mutational analysis in a cohort of 63 unrelated adult probands with left ventricular noncompaction and no other congenital heart anomalies was performed by denaturing high-performance liquid chromatography analysis and direct DNA sequencing of 6 genes encoding sarcomere proteins. Heterozygous mutations were identified in 11 of 63 samples in genes encoding β-myosin heavy chain ( MYH7 ), α-cardiac actin ( ACTC ), and cardiac troponin T ( TNNT2 ). Nine distinct mutations, 7 of them in MYH7 , 1 in ACTC , and 1 in TNNT2 , were found. Clinical evaluations demonstrated familial disease in 6 of 11 probands with sarcomere gene mutations. MYH7 mutations segregated with the disease in 4 autosomal dominant LVNC kindreds. Six of the MYH7 mutations were novel, and 1 encodes a splice-site mutation, a relatively unique finding for MYH7 mutations. Modified residues in β-myosin heavy chain were located mainly within the ATP binding site. Conclusions— We conclude that left ventricular noncompaction is within the diverse spectrum of cardiac morphologies triggered by sarcomere protein gene defects. Our findings support the hypothesis that there is a shared molecular etiology of different cardiomyopathic phenotypes.

31 January 2011 in European Heart Journal
Verified
Journal Article
Open access
PDF file
EOErwin Oechslin
Erwin Oechslin
RJRolf Jenni
Rolf Jenni
Non-compaction of the left ventricular myocardium (LVNC) has gained increasing recognition during the last 25 years. There is a morphological trait of the myocardial structure with a spectrum from normal variants to the pathological phenotype of LVNC, which reflects the embryogenic structure of the human heart due to an arrest in the compaction process during the first trimester. It must be cautioned not to overdiagnose LVNC: the morphological spectrum of trabeculations, from normal variants to pathological trabeculations with the morphological feature of LVNC must be carefully considered. The classical triad of complications are heart failure, arrhythmias, including sudden cardiac death, and systemic embolic events. Non-compaction of the left ventricular myocardium can occur in isolation or in association with congenital heart defects (CHDs), genetic syndromes, and neuromuscular disorders among others. The clinical spectrum is wide and the outcome is more favourable than in previously described populations with a negative selection bias. Familial occurrence is frequent with autosomal dominant and X-linked transmissions. Different mutations in sarcomere protein genes were identified and there seems to be a shared molecular aetiology of different cardiomyopathic phenotypes, including LVNC, hypertrophic and dilated cardiomyopathies. Thus, genetic heterogeneity, with an overlap of different phenotypes, and the variability of hereditary patterns, raise the questions whether there is a morphological trait from dilated/hypertrophic cardiomyopathy to LVNC and what are the triggers and modifiers to develop either dilated, hypertrophic cardiomyopathy, or LVNC in patients with the same mutation. The variety in clinical presentation, the genetic heterogeneity, and the phenotype of the first transgenetic animal model of an LVNC-associated mutation question the hypothesis that LVNC be a distinct cardiomyopathy: it seems to be rather a distinct phenotype or phenotypic, morphological expression of different underlying diseases than a distinct cardiomyopathy.

7 December 2007 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SBSylvette Baldesberger
Sylvette Baldesberger
UBUrs Bauersfeld
Urs Bauersfeld
RCReto Candinas
Reto Candinas
BSBurkhardt Seifert
Burkhardt Seifert
MZMichel Zuber
Michel Zuber
CJChristine H. Attenhofer Jost
Christine H. Attenhofer Jost
Significant brady- and tachyarrhythmias may occur in active endurance athletes. It is controversial whether these arrhythmias do persist after cessation of competitive endurance training. Among all 134 former Swiss professional cyclists [hereafter, former athletes (FAs)] participating at least once in the professional bicycle race Tour de Suisse in 1955–1975, 62 (46%) were recruited for the study. The control group consisted of 62 male golfers matched for age, weight, hypertension, and cardiac medication. All participants were screened with history, clinical and echocardiographic examination, ECG, and 24 h ECG. The time for the last bicycle race of FA s was 38 ± 6 years. The mean age at examination was 66 ± 6 years in controls and 66 ± 7 years in FA s ( P = 0.47). The percentage of study participants with >4 h current cardiovascular training per week was identical. QRS duration (102 ± 20 vs. 95 ± 13 ms, P = 0.03) and corrected QTc interval (416 ± 27 vs. 404 ± 18, P = 0.004) were longer in FA s . There was no significant difference in the number of isolated atrial or ventricular premature complexes, or supraventricular tachycardias in the 24 h ECG; however, ventricular tachycardias tended to occur more often in FA s than in controls (15 vs. 3%, P = 0.05). The average heart rate was lower in FA s (66 ± 9 vs. 70 ± 8 b.p.m.) ( P = 0.004). Paroxysmal or persistent atrial fibrillation or flutter was reported more often in FA s ( P = 0.028). Sinus node disease (SND), defined as bradycardia of 2.5 s (6 vs. 0%), was more common in FA (16%) than in controls (2%, P = 0.006). Observed survival of all FAs was not different from the expected. Among FAs, SND occurred significantly more often compared with age-matched controls, and there is trend towards more frequent ventricular tachycardias. Further studies have to evaluate prevention of arrhythmias with extreme endurance training, the necessity of regular follow-up of heart rhythm, and management of arrhythmias in former competitive endurance athletes.